Correlation of OAS1 gene polymorphism at exon 7 splice accepter site with interferon-based therapy of HCV infection in Pakistan

Viral Immunology

Volumn 27, Issue 3, 2014, Pages 105-111

  Imran, Muhammad ^a   Manzoor, Sobia ^a   Khattak, Nasir Mahmood ^a   Tariq, Muqddas ^a   Khalid, Madiha ^a   Javed, Farakh ^a   Bhatti, Shameem ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; RECOMBINANT INTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; OAS1 PROTEIN, HUMAN; RNA SPLICING;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; EXON; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE BINDING SITE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICE ACCEPTOR SITE; TREATMENT RESPONSE; GENETICS; HEPATITIS C, CHRONIC; MIDDLE AGED; PAKISTAN; RNA SPLICING; TREATMENT OUTCOME; YOUNG ADULT;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PAKISTAN; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA SPLICE SITES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925299574     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2013.0107     Document Type: Article

References (46)

1. Alter MJ, Margolis HS, Bell B, et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47.
2. Argentou N, Vassilopoulos G, Ioannou M, et al. Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders. Leukemia 2014;28:447-449.
3. Ben-Ari Z, Mor E, Papo O, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003;98:144-150.
4. Bonnevie-Nielsen V, Field LL, Lu S, et al. Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am J Hum Genet 2005;76:623-633.
5. Bonnevie-Nielsen V, Martensen PM, Justesen J, et al. The antiviral 2¢, 5¢-oligoadenylate synthetase is persistently activated in type 1 diabetes. Clin Immunol 2000;96:11-18.
6. Choo Q-L, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-362.
7. Czepiel J, Biesiada G, and Mach T. Viral hepatitis C. Pol Arch Med Wewn 2008;118:734-740.
8. Der SD, Zhou A, Williams BR, and Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998;95:15623-15628.
9. El AwadyMK, AnanyMA, Esmat G, et al. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 2011;26:843-850.
10. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of fulllength sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224.
11. Gale M, and Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
12. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
13. Hamano E, Hijikata M, Itoyama S, et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem Biophys Res Commun 2005;329:1234-1239.
14. Hamming OJ, Terczyńska-Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFNk receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J 2013;32:3055-3065.
15. Imran M, Manzoor S, Ashraf J, et al. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 2013;10:299.
16. Imran M, Manzoor S, Khattak NM, et al. Current and future therapies for hepatitis C virus infection: From viral proteins to host targets. Arch Virol 2013;1-16.
17. Justesen J, Hartmann R, and Kjeldgaard N. Gene structure and function of the 2¢-5¢-oligoadenylate synthetase family. Cell Mol Life Sci 2000;57:1593-1612.
18. Kanazawa Y, Hayashi N, Mita E, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994;20:1121-1130.
19. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-639.
20. King JK, Yeh SH, Lin MW, et al. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. Hepatology 2002; 36:1416-1424.
21. Levy DE, and Garća-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001;12:143-156.
22. Lucas M, Mashimo T, Frenkiel M-P, et al. Infection of mouse neurones by West Nile virus is modulated by the interferon-inducible 2¢-5¢ oligoadenylate synthetase 1b protein. Immunol Cell Biol 2003;81:230-236.
23. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050-1056.
24. Mashimo T, Lucas M, Simon-Chazottes D, et al. A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc Natl Acad Sci USA 2002;99:11311-11316.
25. Mashimo T, Simon-Chazottes D, and Guénet J-L. Innate resistance to flavivirus infections and the functions of 2¢-5¢ oligoadenylate synthetases. In: Immunology, Phenotype First: How Mutations Have Established New Principles and Pathways in Immunology. Springer 2008; pp. 85-100.
26. Matsushita M, Hijikata M, Matsushita M, et al. Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients. J Hepatol 1998;29:695-700.
27. Naganuma A, Nozaki A, Tanaka T, et al. Activation of the interferon-inducible 2¢-5¢-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol 2000;74:8744-8750.
28. Nousbaum J-B, Pol S, Nalpas B, et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Int Med 1995;122:161-168.
29. Ohno O, Mizokami M, Wu R-R, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997;35:201-207.
30. Perelygin AA, Scherbik SV, Zhulin IB, et al. Positional cloning of the murine flavivirus resistance gene. Proc Natl Acad Sci USA 2002;99:9322-9327.
31. Rebouillat D, and Hovanessian AG. The human 2', 5'- oligoadenylate synthetase family: Interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res 1999;19:295-308.
32. Safi AZ, Waheed Y, Sadat J, et al. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pacific J Tropical Biomed 2012;2:532-536.
33. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-281.
34. Simmonds P. Genetic diversity and evolution of hepatitis C virus15 years on. J Gen Virol 2004;85:3173-3188.
35. Suh Y, and Vijg J. SNP discovery in associating genetic variation with human disease phenotypes. Mutation Res Fund Mol Mech Mutagenesis 2005;573:41-53.
36. Suzuki F, Arase Y, Suzuki Y, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J Viral Hepat 2004;11:271-276.
37. Talwani R, Gilliam B, Rizza S, et al. Current status of treatment for chronic hepatitis C virus infection. Drugs Today (Barcelona, Spain: 1998). 2012;48:219.
38. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
39. Thursz M. Genetic susceptibility in chronic viral hepatitis. Antiviral Res 2001;52:113-116.
40. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-1094.
41. Van Thiel DH, Friedlander L, Fagiuoli S, et al. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415.
42. Waheed Y, Shafi T, Safi SZ, and Qadri I. Hepatitis C virus in Pakistan: A systematic review of prevalence, genotypes and risk factors. World J Gastroenterol 2009;15:5647.
43. Wu J, Chen T, Huo T, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995;346: 939-941.
44. Wands JR. Prevention of hepatocellular carcinoma. New Engl J Med 2004;351:1567-1570.
45. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-1354.
46. Zhao Y, Kang H, Ji Y, and Chen X. Evaluate the relationship between polymorphisms of OAS1 gene and susceptibility to chronic hepatitis C with high resolution melting analysis. Clin Exp Med 2012;1-6.